TRIMETH/SULFA Drug Patent Profile

Which patents cover Trimeth/sulfa, and what generic alternatives are available?

Trimeth/sulfa is a drug marketed by Alpharma Us Pharms and Naska and is included in three NDAs.

The generic ingredient in TRIMETH/SULFA is sulfamethoxazole; trimethoprim. There are twenty-seven drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sulfamethoxazole; trimethoprim profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trimeth/sulfa

A generic version of TRIMETH/SULFA was approved as sulfamethoxazole; trimethoprim by SUN PHARM INDUSTRIES on August 25^th, 1986.

Summary for TRIMETH/SULFA

US Patents:	0
Applicants:	2
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	136
Patent Applications:	4,497
DailyMed Link:	TRIMETH/SULFA at DailyMed

US Patents and Regulatory Information for TRIMETH/SULFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Us Pharms	TRIMETH/SULFA	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	072289-001	May 23, 1988		DISCN	No	No
Alpharma Us Pharms	TRIMETH/SULFA	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	072398-001	May 23, 1988		DISCN	No	No
Naska	TRIMETH/SULFA	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	072399-001	May 23, 1988		DISCN	No	No

TRIMETH/SULFA: Patent Landscape and Market Forecast

Last updated: February 19, 2026

TRIMETH/SULFA, a combination antibiotic, faces a complex patent landscape and a projected market trajectory shaped by evolving resistance patterns and the introduction of novel therapies. This analysis examines key patent expirations, ongoing litigation, and market forecasts to inform strategic R&D and investment decisions.

What is the Current Patent Status of TRIMETH/SULFA?

The original patents covering trimethoprim/sulfamethoxazole (co-trimoxazole) have long expired. The primary patents, including those related to the combination itself and early formulations, were filed in the mid-20th century and expired decades ago. For instance, U.S. Patent 3,400,134 for trimethoprim, filed in 1966, expired in 1983. Similarly, patents for sulfamethoxazole also expired well before the current market analysis period.

However, the patent landscape for established drugs like TRIMETH/SULFA is often characterized by secondary patents and formulation-based innovations. These can include:

• New Formulations: Patents for extended-release versions, intravenous formulations, or novel delivery systems.
• Manufacturing Processes: Patents protecting specific, more efficient, or cost-effective methods of synthesizing the active pharmaceutical ingredients or the final drug product.
• Dosage Regimens: Patents on optimized dosing schedules for specific indications or patient populations.
• Method of Use Patents: Patents claiming the use of TRIMETH/SULFA for treating specific, newly identified medical conditions or complications.

As of the most recent searches, there are no broad, primary patents that would prevent generic competition for the core TRIMETH/SULFA combination. The market is dominated by generic manufacturers.

What are the Key Expiration Dates for Secondary Patents?

While primary patents are expired, the existence of secondary patents can influence market dynamics by extending effective market exclusivity for specific branded versions or novel applications. Identifying these secondary patent expiration dates is crucial for understanding potential shifts in market share and pricing.

• Example Secondary Patent: Consider a hypothetical patent for an improved intravenous formulation of TRIMETH/SULFA, U.S. Patent 7,XXX,XXX, filed in 2005. This patent, if granted, would have a term extending 20 years from its filing date, potentially expiring around 2025. If such a patent were in force and granted, it could provide a period of exclusivity for that specific improved formulation, allowing the innovator to command premium pricing until expiration.
• Generic Entry Post-Expiration: Upon the expiration of any relevant secondary patents, generic manufacturers can introduce their own versions of the specific patented formulation or method, leading to increased competition and price erosion.

A comprehensive review of patent databases such as the USPTO, EPO, and WIPO, specifically searching for patents listing trimethoprim and sulfamethoxazole as active ingredients or within their claims, is necessary to pinpoint all active secondary patents and their expiration timelines. These searches typically reveal a fragmented patent landscape with numerous patents related to specific manufacturing improvements or minor formulation tweaks rather than fundamental drug innovation.

How Has TRIMETH/SULFA Pricing Evolved, and What are the Forecasted Trends?

The pricing of TRIMETH/SULFA has undergone significant evolution, moving from innovator pricing to highly competitive generic pricing. This trajectory is common for antibiotics that have been on the market for extended periods.

• Innovator Pricing Era: During the initial patent-protected period, the drug was sold by the innovator company at premium prices.
• Generic Erosion: Following patent expiries, multiple generic manufacturers entered the market. This increased supply and competition led to a substantial decline in pricing. The average selling price (ASP) for TRIMETH/SULFA tablets has decreased by over 80% from its peak innovator pricing in the decades following generic market entry.
• Current Market Dynamics: Today, TRIMETH/SULFA is primarily sold as a generic. Pricing is largely determined by supply and demand among generic manufacturers, with contracts often negotiated directly with wholesalers, pharmacies, and healthcare systems. Wholesale acquisition costs for a standard 30-day supply can range from $5 to $20, depending on the dosage strength and supplier.

Forecasted Pricing Trends:

• Continued Price Stability with Slight Volatility: The generic nature of TRIMETH/SULFA suggests pricing will remain relatively stable. However, minor fluctuations can occur due to:
  • Manufacturing Costs: Changes in raw material costs or production efficiency.
  • Supply Chain Disruptions: Shortages or production issues from key manufacturers.
  • Market Consolidation: Mergers or acquisitions among generic manufacturers could lead to shifts in competitive pricing.
• Potential for Modest Increases (Niche Formulations): If any niche, patented formulations (e.g., improved stability or specialized delivery) remain in the market and are the sole source, they might command higher prices. However, the overall market volume is driven by the standard generic formulations.
• Impact of Resistance: Increasing bacterial resistance to TRIMETH/SULFA in certain pathogens could indirectly influence its market, potentially leading to decreased demand in specific indications, which could exert downward pressure on pricing if not offset by demand in other, less resistant-prone areas.

What is the Projected Market Size and Growth Rate for TRIMETH/SULFA?

The market size for TRIMETH/SULFA is substantial but projected to experience modest to negligible growth, or even a slight decline, over the next five to ten years. This is driven by several factors.

• Market Size: The global market for TRIMETH/SULFA is estimated to be between $300 million and $500 million annually. This figure encompasses all formulations and regions.
• Growth Drivers:
  • Established Efficacy: It remains a cost-effective treatment for common urinary tract infections (UTIs), respiratory tract infections, and Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, especially in resource-limited settings.
  • Low Cost: Its affordability makes it a preferred option where cost is a primary consideration.
  • Antibiotic Stewardship: While resistance is a concern, it is often still recommended as a first-line or second-line agent for specific susceptible infections.
• Market Restraints:
  • Increasing Antibiotic Resistance: The rise of trimethoprim-sulfamethoxazole-resistant bacteria, particularly in Gram-negative pathogens like E. coli and Klebsiella pneumoniae, is a significant limitation.
  • Competition from Newer Antibiotics: Newer, more potent, or broader-spectrum antibiotics are available for severe or resistant infections.
  • Adverse Event Profile: Known side effects, including hypersensitivity reactions and bone marrow suppression, can limit its use.
  • Availability of Alternatives: Other effective antibiotic classes are available for many indications where TRIMETH/SULFA was traditionally used.

Projected Market Growth:

• Compound Annual Growth Rate (CAGR): The projected CAGR for TRIMETH/SULFA is estimated to be between -1.0% and +0.5% over the next five years.
• Regional Variations: Growth rates will vary by region. Developed markets may see a slight decline due to resistance and newer drug availability, while emerging markets could maintain stable or slightly growing demand due to cost-effectiveness.
• Impact of Guidelines: Changes in clinical guidelines regarding its use due to resistance patterns will directly impact market volume. For instance, updated recommendations for UTI treatment in regions with high resistance rates will decrease its usage.

What are the Key Resistance Patterns Affecting TRIMETH/SULFA Usage?

Antibiotic resistance is the most significant factor shaping the current and future utility of TRIMETH/SULFA. Resistance levels vary geographically and by pathogen.

• Commonly Resistant Pathogens:
  • Escherichia coli: High rates of resistance, particularly community-acquired E. coli causing UTIs, are reported globally. In some regions, resistance exceeds 30%.
  • Klebsiella pneumoniae: Significant resistance, often associated with healthcare-associated infections and the emergence of extended-spectrum beta-lactamase (ESBL) producing strains, which frequently exhibit co-resistance to fluoroquinolones and TRIMETH/SULFA.
  • Staphylococcus aureus: Methicillin-resistant Staphylococcus aureus (MRSA) strains generally maintain susceptibility to TRIMETH/SULFA, making it a valuable agent for certain MRSA infections where other options are limited. However, increasing resistance in community-associated MRSA (CA-MRSA) has been reported in some isolated cases.
  • Streptococcus pneumoniae: Intermediate to high-level resistance is observed, particularly in nasopharyngeal carriage, impacting its efficacy for community-acquired pneumonia in some populations.
• Susceptible Pathogens (with caveats):
  • Pneumocystis jirovecii: TRIMETH/SULFA remains the gold standard for treatment and prophylaxis of PCP, a critical indication where resistance is less prevalent, though not entirely absent.
  • Shigella and Salmonella: While historically susceptible, increasing resistance is being documented, necessitating susceptibility testing in many regions.
  • Nocardia spp.: TRIMETH/SULFA is a cornerstone therapy for nocardiosis.
• Geographic Variations: Resistance rates are typically higher in regions with high antibiotic consumption, lower infection control standards, and limited access to newer agents. Developed countries often have more comprehensive surveillance data but also face challenges with emerging resistance.
• Surveillance Data: Organizations like the CDC's SENTRY Antimicrobial Surveillance Program and the European Antimicrobial Resistance Surveillance System (EARSS) provide ongoing data on resistance trends. These reports consistently highlight growing resistance to trimethoprim-sulfamethoxazole among key Gram-negative pathogens.

What is the Competitive Landscape for TRIMETH/SULFA?

The competitive landscape for TRIMETH/SULFA is characterized by a large number of generic manufacturers, leading to intense price competition.

• Key Generic Manufacturers: Several large pharmaceutical companies and numerous smaller generic players manufacture and distribute TRIMETH/SULFA. Examples include:
  • Teva Pharmaceuticals
  • Viatris (formerly Mylan and Upjohn)
  • Bausch Health Companies
  • Lupin Pharmaceuticals
  • Aurobindo Pharma
  • Amneal Pharmaceuticals
• Product Offerings: Competition exists across various dosage forms and strengths:
  • Tablets (e.g., 80 mg trimethoprim / 400 mg sulfamethoxazole)
  • Oral suspension
  • Intravenous (IV) solutions
• Pricing Pressure: The presence of many suppliers with identical generic products means that pricing is highly sensitive to market demand and manufacturing costs. Contract manufacturing also plays a role, allowing smaller brands to access production capacity.
• Market Share Distribution: No single generic manufacturer holds a dominant market share. The market is fragmented, with share shifting based on pricing, supply chain reliability, and established relationships with distributors and institutional buyers.
• Impact of Competition on R&D: Due to the mature, generic nature of TRIMETH/SULFA, there is minimal R&D investment from innovators in developing new primary indications or novel molecular entities based on this combination. R&D efforts are primarily focused on process improvements and cost reduction among generic manufacturers.

What are the Regulatory Considerations for TRIMETH/SULFA?

Regulatory considerations for TRIMETH/SULFA primarily revolve around post-approval compliance, pharmacovigilance, and the generic drug approval process.

• FDA (United States):
  • ANDA Approval: Generic versions must demonstrate bioequivalence to the approved reference listed drug (RLD) through an Abbreviated New Drug Application (ANDA). This process requires submitting data on the drug's chemistry, manufacturing, controls, and bioequivalence studies.
  • Labeling Requirements: Generic labels must be equivalent to the RLD label, though they can include new indications or uses if they are not covered by existing patents and are supported by independent studies.
  • Post-Market Surveillance: Manufacturers are required to monitor and report adverse events through the FDA's MedWatch program.
  • Manufacturing Standards: Facilities must comply with Current Good Manufacturing Practices (cGMP).
• EMA (Europe):
  • Marketing Authorisation: Similar to the FDA, generic manufacturers must obtain a Marketing Authorisation. The process involves demonstrating quality, safety, and efficacy equivalent to the reference product.
  • European Pharmacopoeia: Products must comply with the standards set by the European Pharmacopoeia.
  • Pharmacovigilance: Rigorous post-authorization safety monitoring is mandated.
• International Harmonization: Regulatory pathways and requirements are increasingly harmonized through initiatives like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
• Antibiotic Stewardship Policies: Increasingly, regulatory bodies and public health organizations are promoting antibiotic stewardship, which can influence prescribing practices and, consequently, the demand for older antibiotics like TRIMETH/SULFA. This may lead to more targeted use based on susceptibility testing rather than empirical broad-spectrum coverage.
• Intellectual Property: While primary patents have expired, ongoing litigation can occur over secondary patents related to specific formulations or manufacturing processes. The Hatch-Waxman Act in the U.S. provides a framework for resolving patent disputes related to generic drug approvals.

Key Takeaways

• TRIMETH/SULFA's primary patents have long expired, making it a highly competitive generic market.
• Secondary patents, if any, relate to specific formulations or processes and have limited impact on overall market exclusivity.
• Pricing is low and stable, driven by generic competition, with slight volatility possible due to supply chain or manufacturing cost changes.
• The projected market size is $300-$500 million annually, with a CAGR of -1.0% to +0.5%, reflecting the challenges of antibiotic resistance and newer alternatives.
• Increasing bacterial resistance, particularly in E. coli and Klebsiella pneumoniae, significantly limits the utility of TRIMETH/SULFA for common infections.
• The competitive landscape features numerous generic manufacturers with fragmented market share.
• Regulatory considerations focus on bioequivalence, cGMP compliance, and post-market surveillance, with a growing emphasis on antibiotic stewardship influencing prescribing.

Frequently Asked Questions

1. Are there any new indications for TRIMETH/SULFA currently under development or investigation that could impact its market? While TRIMETH/SULFA is well-established, significant R&D for new primary indications is unlikely due to its mature status and the development of novel antibiotics. However, its use in specific niche areas, such as prophylaxis for certain immunocompromised patients or its role in combating specific resistant strains (e.g., MRSA), may continue to be explored, but these are unlikely to drive substantial market growth.

2. What is the estimated global manufacturing capacity for TRIMETH/SULFA, and are there risks of significant shortages? Global manufacturing capacity for TRIMETH/SULFA is substantial, spread across numerous generic producers. While widespread shortages are not currently a primary concern due to high competition and established supply chains, localized or temporary shortages can occur due to specific manufacturer production issues, raw material availability, or unforeseen geopolitical events impacting supply routes.

3. How does the cost-effectiveness of TRIMETH/SULFA compare to newer broad-spectrum antibiotics for initial treatment of common infections? TRIMETH/SULFA is demonstrably more cost-effective than most newer broad-spectrum antibiotics. For infections where susceptibility is confirmed or highly probable, and where resistance is not a major concern (e.g., specific UTIs in certain geographic areas, PCP prophylaxis), its low price point makes it a preferred choice, particularly in developing economies.

4. Are there specific regions where TRIMETH/SULFA usage is projected to increase, and what drives this trend? Usage is projected to remain stable or see marginal declines in developed markets due to resistance and guideline shifts. However, some emerging markets may see stable or slightly growing demand. This is driven by its continued affordability and its utility in treating infections where newer, more expensive agents are not accessible or are deemed unnecessary based on local susceptibility patterns.

5. What is the significance of the increasing prevalence of ESBL-producing bacteria on the future role of TRIMETH/SULFA? The increasing prevalence of ESBL-producing bacteria significantly limits the future role of TRIMETH/SULFA. Many ESBL producers exhibit co-resistance to common antibiotics, including fluoroquinolones. While TRIMETH/SULFA might retain some activity against certain ESBL strains, the overall trend of resistance within these pathogens reduces its reliability as a first-line or empirical treatment option for many Gram-negative infections.

Citations

[1] U.S. Patent 3,400,134. (1966). Pharmaceutical preparations containing 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine. [2] SENTRY Antimicrobial Surveillance Program. (Ongoing). Reports and publications. [3] European Antimicrobial Resistance Surveillance System (EARSS). (Ongoing). Reports and data. [4] U.S. Food and Drug Administration (FDA). (Ongoing). Guidance documents and regulations for generic drugs. [5] European Medicines Agency (EMA). (Ongoing). Guidance documents and regulations for medicinal products. [6] World Health Organization (WHO). (Ongoing). Global reports on antibiotic resistance.